Clinical Impact of Omitting Fluoroquinolones for Primary Neutropenic Prophylaxis in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia
Document Type
Conference Proceeding - Restricted Access
Publication Date
5-9-2025
Abstract
Intensive induction chemotherapy for the treatment of acute myeloid leukemia (AML) places patients at high risk for febrile neutropenia and profound, protracted neutropenia. The use of fluoroquinolone prophylaxis in this population became standard of practice for this patient population and is a recommendation by the most recent Infectious Disease Society of America (IDSA) and National Cancer Care Network (NCCN) guidelines. However, the recent emergence of multidrug-resistant organisms has caused the use of fluoroquinolone prophylaxis to be reconsidered. Alternative practice guidelines contain conflicting opinions regarding the use of fluoroquinolone prophylaxis in AML patients. Thus, practice patterns vary in the US. Further research in the modern era is needed to fully understand the clinical impact of omitting fluoroquinolone prophylaxis for primary neutropenia in patients with AML.
Recommended Citation
Gotberg E, Van Rossum B, Polkowski M, Stonerock D. Clinical impact of omitting fluoroquinolones for primary neutropenic prophylaxis in adult patients with newly diagnosed acute myeloid leukemia. Presented at: Research Day Corewell Health West; 2025 May 9; Grand Rapids, MI.
Comments
2025 Research Day Corewell Health West, Grand Rapids, MI, May 9, 2025. Abstract 1814